

Our ref: IG/FOI/FOI.279.25

2 May 2025

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information which was received on 09 April 2025, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does hold the information that you require. For ease of reference your request is set out below and my response follows each question individually.

Your Freedom of Information (FOI) Request and Powys Response (Bold):

I am writing to request information under the Freedom of Information Act 2000. I am requesting the following information in respect of:

Diabetes:

- SMBG test strips
- Pen needles and safety pen needles
- CGM - Continuous Glucose monitoring systems

Contenance:

- Leg Bags
- Drainage/night bags
- ISC catheters
- Foley catheters
- Incontinence sheaths

For each area:

Q1. The name(s) and direct contact email address(es) and direct telephone numbers of the person(s) who are responsible for the formulary.

Please note: Powys Teaching Health Board (PTHB) is withholding the name and contact details of the member of staff whose job may fit the title. This decision has been made as it is not within the expectations of the individual that their personal data would be put into the public

domain. This information is classed as personal data of third parties and is therefore being withheld in accordance with section 40 (2) of the Freedom of Information Act 2000 (the Act) by virtue of section 40 (3) (a) (i) of the Act which permits a public authority to withhold personal data other than the requester's where the disclosure would breach a Data Protection Principle.

The Data Protection Act 2018 (DPA) / General Data Protection Regulation (GDPR) defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.

Diabetes: Principal Pharmacist Formulary Management and High Cost Drugs and Senior Pharmacy Technician Formulary Management and High Cost Drugs.

Email: newmedicines.powys@wales.nhs.uk

**Contenance: Powys Contenance Service, Contenance Service Manager.
Telephone: 01686 414218**

Email: contenanceservice.pow@wales.nhs.uk

Q2. The date of the next review of your formulary.

Diabetes: I can confirm:

- Continuous glucose monitoring systems are currently under review, to be discussed at the Formulary Working Group on a date to be confirmed.**
- Test strips are as per the All-Wales Self Testing Blood Glucose Formulary.**
- Pen needles are also due to be reviewed within the next quarter.**

Contenance: I can confirm the current formulary was approved January 2025 with a review to be commenced in June/July 2027 and a completion/approval for January 2028.

Q3. Details of how you intend to review your formulary (include process, timelines).

Diabetes: Powys Teaching Health Boards (PTHB) formulary is reviewed by the formulary team on a rolling basis with every chapter due to be reviewed within a two-year cycle. It is reviewed in accordance with local and national guidance, with a consideration of cost-effectiveness.

Contenance: I can confirm emails are sent to company representatives for expression of interest to demonstrate products for consideration (April/May 2027). Those that respond receive a confirmation email with date and time of their presentation slot (June/July 2027). There is a 15-minute presentation followed by Questions and Answers (Q&A). Present in the room are clinicians from Powys Contenance Service and a representative of Medicines Management Service. Any product samples/ literature is retained by the clinical team for further checks and discussion. After the presentation day, no further engagement

takes place with the companies with respect to the formulary until final approval. Continence Service Manager produces data sheet with products demonstrated and cross references with costs on drug tariff. Discussion within clinical team and products narrowed. Further discussions with service manager and medicines management with narrative from service manager with respect to products chosen. The Medicines Management representative will then take forward to their groups with final approval at Area Prescribing Group (APG) by January 2028.

Q4. Details if part of a local partnership arrangement for formulary review. Please provide the contact's name, email address and telephone number for the person with responsibility where a partnership arrangement is in place.

Diabetes: The local diabetes formulary will be reviewed jointly between PTHB Diabetes team and our Medicines Management team. Changes and decisions made will be ratified at the PTHB Area Prescribing Group. The Medicines Management Formulary Pharmacist and Pharmacy Technician can be contacted via newmedicines.powys@wales.nhs.uk

Continence: Medicines Management representative provides oversight and scrutiny of the process. The final decision remains with the clinicians and service manager. The Medicines Management Formulary Pharmacist and Pharmacy Technician can be contacted via newmedicines.powys@wales.nhs.uk


Under the terms of the Health Board's Freedom of Information procedure, individuals seeking access to recorded information held by the Health Board are entitled to request an internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request, please contact us directly at the address below or register your complaint via powys.foi@wales.nhs.uk

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 0330 414 6421.

Yours sincerely



**David Farnsworth
Assistant Director, Community Services Group**



**Richard Stratton
Assistant Medical Director-Primary Care**

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.